Lv1
48 积分 2022-11-10 加入
Ziftomenib (KO-539): a potent and selective Menin inhibitor for the treatment of recurrent or refractory acute myeloid leukemia
7小时前
已关闭
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
10天前
已完结
Menin inhibitors for adult acute myeloid leukemia: 2025 update
12天前
已完结
Advances and challenges in the purification of recombinant coagulation factors: A review
5个月前
已完结
Demographics, clinical profile and treatment landscape of patients with haemophilia B in China
6个月前
已完结
皖公网安备34019202002308
